Insider Trading activities of Biomimetic Therapeutics, Inc. insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Biomimetic Therapeutics, Inc. since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Biomimetic Therapeutics, Inc. since year 2005. Table 2 shows the detailed insider transactions of Biomimetic Therapeutics, Inc. since 2005. The reporting company's ticker symbol is BMTI. The reporting company's CIK number is 1138400.
The total value of stock buying since 2005 is $40,573,427.
The total value of stock sales since 2005 is $6,478,994.
The total value of stock option exercises since 2005 is $4,405,874.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Biomimetic Therapeutics, Inc. (BMTI).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2013-03 0 $0 0 $0 484,680 $1,575,235
2013-01 0 $0 1,381 $11,187 0 $0
2012-04 10,000 $27,919 0 $0 0 $0
2012-03 128,550 $300,436 56,999 $133,945 0 $0
2011-10 0 $0 30,000 $89,283 0 $0
2011-06 0 $0 6,500 $37,030 0 $0
2011-05 14,900 $116,828 0 $0 0 $0
2011-04 0 $0 0 $0 7,500 $59,700
2011-01 0 $0 771 $10,272 0 $0
2010-12 0 $0 0 $0 63,750 $231,412
2010-10 0 $0 1,829 $22,321 0 $0
2010-09 0 $0 0 $0 9,720 $35,283
2010-08 0 $0 0 $0 19,970 $72,490
2010-07 1,000,000 $8,500,000 0 $0 0 $0
2010-03 0 $0 5,000 $66,500 262,023 $951,143
2010-01 0 $0 12,799 $155,123 71,000 $257,730
2009-12 0 $0 18,000 $208,140 10,000 $36,300
2009-11 0 $0 12,000 $140,310 0 $0
2009-10 0 $0 16,500 $217,363 0 $0
2009-09 0 $0 15,000 $189,296 0 $0
2009-08 0 $0 12,000 $134,472 0 $0
2009-07 0 $0 15,000 $146,866 0 $0
2009-06 352,088 $2,992,748 15,000 $136,269 19,035 $67,517
2009-04 947,177 $8,040,732 0 $0 0 $0
2009-03 0 $0 1,200 $10,140 0 $0
2009-01 50,000 $481,400 50,000 $481,400 0 $0
2008-11 500 $4,000 0 $0 0 $0
2008-10 0 $0 0 $0 84,750 $279,262
2008-09 227,234 $2,380,915 0 $0 0 $0
2008-08 19,202 $208,926 0 $0 47,500 $136,325
2008-07 5,146 $56,606 0 $0 0 $0
2008-06 248,202 $2,730,222 0 $0 0 $0
2008-05 224,273 $2,348,763 0 $0 0 $0
2008-04 344,285 $3,407,424 0 $0 8,500 $30,855
2008-03 30,975 $275,653 0 $0 103,250 $315,975
2008-01 3,500 $53,329 0 $0 0 $0
2007-12 0 $0 14,000 $237,579 0 $0
2007-09 6,500 $97,012 0 $0 0 $0
2007-08 0 $0 0 $0 24,000 $31,920
2007-06 0 $0 0 $0 108,750 $324,727
2007-02 0 $0 236,239 $4,051,498 0 $0
2007-01 671,150 $8,360,514 0 $0 0 $0
2006-05 23,750 $190,000 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Biomimetic Therapeutics, Inc. insiders (BMTI)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2013-03-01 Pagano Russell P. (VP, Reg. & Clinical Affairs) Option Ex 70,000 2.08 145,600
2013-03-01 Friedlaender Gary E (Director) Option Ex 38,736 4.22 163,272
2013-03-01 Lynch Samuel Eugene (President and CEO) Option Ex 221,000 2.78 613,275
2013-03-01 Murphy James G (Director) Option Ex 38,736 4.22 163,272
2013-03-01 Papasan Larry W (Director) Option Ex 38,736 4.22 163,272
2013-03-01 Federico Charles (Director) Option Ex 38,736 4.22 163,272
2013-03-01 Watson Douglas G (Director) Option Ex 38,736 4.22 163,272
2013-01-22 Pagano Russell P. (VP, Reg. & Clinical Affairs) Sale 1,381 8.10 11,187
2012-04-02 Friedlaender Gary E (Director) Buy 10,000 2.79 27,919
2012-03-30 Lynch Samuel Eugene (President and CEO) Buy 39,362 2.43 95,649
2012-03-29 Pagano Russell P. (VP, Reg. & Clinical Affairs) Sale 3,438 2.36 8,127
2012-03-29 Lynch Samuel Eugene (President and CEO) Buy 30,638 2.38 72,887
2012-03-28 Douglas Earl Martin (General Counsel) Sale 47,461 2.35 111,533
2012-03-27 Douglas Earl Martin (General Counsel) Sale 5,000 2.34 11,700
2012-03-27 Papasan Larry W (Director) Buy 10,400 2.32 24,148
2012-03-26 Douglas Earl Martin (General Counsel) Sale 1,100 2.35 2,585
2012-03-23 Lynch Samuel Eugene (President and CEO) Buy 13,150 2.35 30,902
2012-03-20 Bullock Lawrence E (Chief Financial Officer) Buy 17,670 2.20 38,874
2012-03-19 Friedlaender Gary E (Director) Buy 15,000 2.19 32,850
2012-03-19 Bullock Lawrence E (Chief Financial Officer) Buy 2,330 2.20 5,126
2011-10-14 Douglas Earl Martin (General Counsel) Sale 3,000 3.06 9,165
2011-10-13 Douglas Earl Martin (General Counsel) Sale 3,000 2.98 8,943
2011-10-12 Douglas Earl Martin (General Counsel) Sale 3,000 2.99 8,970
2011-10-11 Douglas Earl Martin (General Counsel) Sale 3,000 3.00 9,015
2011-10-10 Douglas Earl Martin (General Counsel) Sale 3,000 2.97 8,910
2011-10-07 Douglas Earl Martin (General Counsel) Sale 3,000 3.02 9,045
2011-10-06 Douglas Earl Martin (General Counsel) Sale 3,000 2.99 8,964
2011-10-05 Douglas Earl Martin (General Counsel) Sale 3,000 2.94 8,835
2011-10-04 Douglas Earl Martin (General Counsel) Sale 3,000 2.89 8,679
2011-10-03 Douglas Earl Martin (General Counsel) Sale 3,000 2.92 8,757
2011-06-10 Papasan Larry W (Director) Sale 6,500 5.70 37,030
2011-05-19 Pagano Russell P. (VP, Reg. & Clinical Affairs) Buy 1,900 7.95 15,103
2011-05-18 Lynch Samuel Eugene (President and CEO) Buy 13,000 7.82 101,725
2011-04-25 Friedlaender Gary E (Director) Option Ex 7,500 7.96 59,700
2011-01-25 Pagano Russell P. (VP, Reg. & Clinical Affairs) Sale 771 13.32 10,272
2010-12-30 Lynch Samuel Eugene (President and CEO) Option Ex 26,250 3.63 95,287
2010-12-03 Bullock Lawrence E (Chief Financial Officer) Option Ex 37,500 3.63 136,125
2010-10-18 Pagano Russell P. (VP, Reg. & Clinical Affairs) Sale 1,829 12.20 22,321
2010-09-07 Murphy James G (Director) Option Ex 9,720 3.63 35,283
2010-08-23 Friedlaender Gary E (Director) Option Ex 10,250 3.63 37,207
2010-08-23 Papasan Larry W (Director) Option Ex 9,720 3.63 35,283
2010-07-15 Novo A/s (10% Owner) Buy 1,000,000 8.50 8,500,000
2010-03-23 Hirsch Steven Neal (COO & Executive VP) Option Ex 236,523 3.63 858,578
2010-03-17 Douglas Earl Martin (General Counsel) Sale 5,000 13.30 66,500
2010-03-17 Douglas Earl Martin (General Counsel) Option Ex 25,500 3.63 92,565
2010-01-13 Douglas Earl Martin (General Counsel) Sale 12,799 12.12 155,123
2010-01-13 Douglas Earl Martin (General Counsel) Option Ex 37,000 3.63 134,310
2010-01-02 Douglas Earl Martin (General Counsel) Option Ex 34,000 3.63 123,420
2009-12-29 Lynch Samuel Eugene (President and CEO) Sale 3,000 11.29 33,870
2009-12-28 Lynch Samuel Eugene (President and CEO) Sale 3,000 11.56 34,680
2009-12-22 Friedlaender Gary E (Director) Option Ex 10,000 3.63 36,300
2009-12-15 Lynch Samuel Eugene (President and CEO) Sale 3,000 12.03 36,090
2009-12-14 Lynch Samuel Eugene (President and CEO) Sale 3,000 12.32 36,960
2009-12-03 Lynch Samuel Eugene (President and CEO) Sale 3,000 11.24 33,720
2009-12-02 Lynch Samuel Eugene (President and CEO) Sale 3,000 10.94 32,820
2009-11-17 Lynch Samuel Eugene (President and CEO) Sale 3,000 11.64 34,920
2009-11-16 Lynch Samuel Eugene (President and CEO) Sale 3,000 11.80 35,400
2009-11-05 Lynch Samuel Eugene (President and CEO) Sale 3,000 11.70 35,100
2009-11-04 Lynch Samuel Eugene (President and CEO) Sale 3,000 11.63 34,890
2009-10-21 Lynch Samuel Eugene (President and CEO) Sale 4,500 13.85 62,325
2009-10-20 Lynch Samuel Eugene (President and CEO) Sale 4,500 14.22 63,967
2009-10-06 Lynch Samuel Eugene (President and CEO) Sale 4,500 12.57 56,556
2009-10-05 Lynch Samuel Eugene (President and CEO) Sale 3,000 11.50 34,515
2009-09-24 Lynch Samuel Eugene (President and CEO) Sale 4,500 12.98 58,432
2009-09-23 Lynch Samuel Eugene (President and CEO) Sale 4,500 13.08 58,864
2009-09-10 Lynch Samuel Eugene (President and CEO) Sale 3,000 11.99 35,982
2009-09-09 Lynch Samuel Eugene (President and CEO) Sale 3,000 12.01 36,018
2009-08-26 Lynch Samuel Eugene (President and CEO) Sale 3,000 11.47 34,404
2009-08-25 Lynch Samuel Eugene (President and CEO) Sale 3,000 11.72 35,151
2009-08-13 Lynch Samuel Eugene (President and CEO) Sale 3,000 10.79 32,376
2009-08-12 Lynch Samuel Eugene (President and CEO) Sale 3,000 10.85 32,541
2009-07-30 Lynch Samuel Eugene (President and CEO) Sale 3,000 10.09 30,272
2009-07-29 Lynch Samuel Eugene (President and CEO) Sale 3,000 9.84 29,535
2009-07-17 Lynch Samuel Eugene (President and CEO) Sale 3,000 9.78 29,339
2009-07-16 Lynch Samuel Eugene (President and CEO) Sale 3,000 9.88 29,625
2009-07-01 Lynch Samuel Eugene (President and CEO) Sale 3,000 9.36 28,095
2009-06-30 Lynch Samuel Eugene (President and CEO) Sale 3,000 9.28 27,852
2009-06-26 Watson Douglas G (Director) Option Ex 19,035 3.55 67,517
2009-06-25 Novo A/s (10% Owner) Buy 343,406 8.50 2,918,951
2009-06-25 Friedlaender Gary E (Director) Buy 8,174 8.50 69,479
2009-06-25 Murphy James G (Director) Buy 508 8.50 4,318
2009-06-17 Lynch Samuel Eugene (President and CEO) Sale 3,000 9.03 27,078
2009-06-16 Lynch Samuel Eugene (President and CEO) Sale 3,000 9.00 27,000
2009-06-04 Lynch Samuel Eugene (President and CEO) Sale 3,000 9.07 27,204
2009-06-03 Lynch Samuel Eugene (President and CEO) Sale 3,000 9.04 27,135
2009-04-07 Ehrlich Christopher B (Director) Buy 941,177 8.50 8,000,004
2009-04-01 Bullock Lawrence E (Chief Financial Officer) Buy 6,000 6.79 40,728
2009-03-17 Douglas Earl Martin (General Counsel) Sale 1,200 8.45 10,140
2009-01-29 Novo A/s (10% Owner) Buy 50,000 9.63 481,400
2009-01-29 Lynch Samuel Eugene (President and CEO) Sale 50,000 9.63 481,400
2008-11-11 Novo A/s (10% Owner) Buy 500 8.00 4,000
2008-10-27 Friedlaender Gary E (Director) Option Ex 7,500 .67 5,025
2008-10-27 Lynch Samuel Eugene (President and CEO) Option Ex 77,250 3.55 274,237
2008-09-09 Novo A/s (10% Owner) Buy 172 10.47 1,800
2008-09-08 Novo A/s (10% Owner) Buy 20,000 10.53 208,554
2008-09-05 Novo A/s (10% Owner) Buy 24,700 10.33 255,126
2008-09-04 Novo A/s (10% Owner) Buy 78,407 10.43 819,218
2008-09-03 Novo A/s (10% Owner) Buy 18,100 10.84 196,276
2008-09-02 Novo A/s (10% Owner) Buy 10,000 10.77 108,074
2008-08-29 Novo A/s (10% Owner) Buy 10,202 10.83 110,487
2008-08-28 Novo A/s (10% Owner) Buy 1,700 10.88 18,504
2008-08-27 Novo A/s (10% Owner) Buy 7,300 10.95 79,935
2008-08-04 Hart Charles Edward (Chief Scientific Officer &VP) Option Ex 47,500 2.87 136,325
2008-07-07 Novo A/s (10% Owner) Buy 5,146 11.00 56,606
2008-06-24 Novo A/s (10% Owner) Buy 248,202 11.00 2,730,222
2008-05-22 Novo A/s (10% Owner) Buy 12,931 10.95 141,594
2008-05-13 Novo A/s (10% Owner) Buy 7,843 10.96 85,927
2008-05-09 Novo A/s (10% Owner) Buy 25,100 10.87 272,937
2008-05-08 Novo A/s (10% Owner) Buy 30,739 10.39 319,156
2008-05-07 Novo A/s (10% Owner) Buy 21,561 10.39 223,235
2008-05-06 Novo A/s (10% Owner) Buy 34,100 10.28 347,381
2008-05-05 Novo A/s (10% Owner) Buy 39,182 10.63 416,387
2008-05-02 Novo A/s (10% Owner) Buy 700 10.50 7,350
2008-04-29 Novo A/s (10% Owner) Buy 253,693 9.88 2,506,233
2008-04-28 Novo A/s (10% Owner) Buy 44,200 10.02 439,801
2008-04-25 Novo A/s (10% Owner) Buy 11,392 10.08 114,785
2008-04-14 Douglas Earl Martin (General Counsel) Option Ex 8,500 3.63 30,855
2008-03-31 Hart Charles Edward (Chief Scientific Officer &VP) Option Ex 35,000 2.87 100,450
2008-03-28 Friedlaender Gary E (Director) Buy 8,500 8.99 76,440
2008-03-28 Douglas Earl Martin (General Counsel) Buy 1,000 9.05 9,050
2008-03-28 Lynch Samuel Eugene (President and CEO) Buy 5,400 8.93 48,227
2008-03-28 Murphy James G (Director) Buy 5,000 8.40 42,000
2008-03-28 Federico Charles (Director) Buy 1,075 9.24 9,936
2008-03-28 Bullock Lawrence E (Chief Financial Officer) Buy 10,000 9.00 90,000
2008-03-27 Watson Douglas G (Director) Option Ex 21,375 2.91 62,244
2008-03-05 Monsor James A. (VP - Operations) Option Ex 46,875 3.27 153,281
2008-01-23 Douglas Earl Martin (General Counsel) Buy 3,500 15.24 53,329
2007-12-31 Monsor James A. (VP - Operations) Sale 14,000 16.97 237,579
2007-09-11 Papasan Larry W (Director) Buy 6,500 14.92 97,012
2007-08-30 Monsor James A. (VP - Operations) Option Ex 24,000 1.33 31,920
2007-06-04 Citron Mark Barry (Other) Option Ex 108,750 2.99 324,727
2007-02-14 Lynch Samuel Eugene (President and CEO) Sale 236,239 17.15 4,051,498
2007-01-25 Novo A/s (10% Owner) Buy 335,575 12.46 4,180,257
2007-01-25 Dyrberg Thomas (Director) Buy 335,575 12.46 4,180,257
2006-05-15 Ehrlich Christopher B (Director) Buy 1,250 8.00 10,000
2006-05-12 Lynch Samuel Eugene (President and CEO) Buy 12,500 8.00 100,000
2006-05-12 Bullock Lawrence E (Chief Financial Officer) Buy 10,000 8.00 80,000

Insider trading activities including stock purchases, stock sales, and option exercises of BMTI listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Biomimetic Therapeutics, Inc. (symbol BMTI, CIK number 1138400) see the Securities and Exchange Commission (SEC) website.